

What is claimed is:

1. A method for treating unwanted neovasculture in a subject, comprising;
 - (a) administering an effective amount of an anti-angiogenic agent to the subject;
 - (b) administering an effective amount of a photosensitive agent to the subject; and
 - (c) irradiating the unwanted neovasculture with light having a wavelength absorbable by the photosensitive agent.
2. The method of claim 1, wherein the anti-angiogenic agent is administered between about 0 and about 4 weeks before the administration of the photosensitive agent.
3. The method of claim 1, wherein the anti-angiogenic agent and the photosensitive agent are administered simultaneously.
4. The method of claim 1, wherein the anti-angiogenic agent is administered between about 0 and about 4 weeks after the administration of the photosensitive agent.
5. The method of claim 1, wherein the anti-angiogenic agent is administered between about 0 and about 4 weeks before the administration of the photosensitive agent and between about 0 and about 4 weeks after the administration of the photosensitive agent.
6. The method of claim 1, wherein the anti-angiogenic agent is selected from the group consisting of inhibitors of protein kinase C, antagonists of growth hormone, antagonists of IGF-1, antagonists of vascular endothelial growth factor, inhibitors of cyclooxygenase II, antagonists of angiotensin II, antagonists of NF-kappa B, and phospholipase A2 antagonists.
7. The method of claim 6, wherein the anti-angiogenic agent is selected from the group consisting of inhibitors of protein kinase C and antagonists of vascular endothelial growth factor.

8. The method of claim 7, wherein the anti-angiogenic agent is an inhibitor of protein kinase C.
9. The method of claim 7, wherein the anti-angiogenic agent is selected from the group consisting of N-benzoyl-staurosporine, CGP 79787, and octreotide.
10. The method of claim 9, wherein the anti-angiogenic agent is N-benzoyl-staurosporine.
11. The method of claim 1, wherein the photosensitive agent is selected from the group consisting of a porphyrin and a purpurin.
12. The method of claim 11, wherein the photosensitive agent is benzoporphyrin derivative monacid ring A.
13. The method of claim 2, wherein multiple administrations of anti-angiogenic agent are performed prior to the administration of the photosensitive agent.
14. The method of claim 4, wherein multiple administrations of anti-angiogenic agent are performed after the administration of the photosensitive agent.
15. The method of claim 5, wherein multiple administrations of anti-angiogenic agent are performed prior to the administration of the photosensitive agent and wherein multiple administrations of anti-angiogenic agent are performed after the administration of the photosensitive agent.
16. A kit comprising at least one anti-angiogenic agent and at least one photosensitive agent.
17. The kit of claim 17, wherein the photosensitive agent is benzoporphyrin derivative monoacid ring A.

18. The method of claim 1, wherein the subject is suffering from choroidal neovascularization.
19. The method of claim 1, wherein the subject is suffering from retinal neovascularization.